Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune intervention in type 1 diabetes.

Literature DB >> 21852151

Immune intervention in type 1 diabetes.

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the specific immune destruction of insulin producing beta cells. Currently there is no cure for T1D and treatment for the disease consists of lifelong administration of insulin. Immunotherapies aimed at preventing beta cell destruction in T1D patients with residual c-peptide or in individuals developing T1D are being evaluated. Networks of researchers such as TrialNet and the Immune Tolerance Network in the U.S. and similar networks in Europe have been established to evaluate such immunotherapies. This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antigens
Dietary Proteins

Year: 2011 PMID： 21852151 PMCID： PMC3177994 DOI： 10.1016/j.smim.2011.07.003

Source DB: PubMed Journal: Semin Immunol ISSN： 1044-5323 Impact factor: 11.130

79 in total

Review 1. IL-1 pathways in inflammation and human diseases.

Authors: Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal: Nat Rev Rheumatol Date: 2010-02-23 Impact factor: 20.543

2. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.

Authors: Maria Hjorth; Stina Axelsson; Anna Rydén; Maria Faresjö; Johnny Ludvigsson; Rosaura Casas
Journal: Clin Immunol Date: 2010-11-01 Impact factor: 3.969

3. Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors:
Journal: N Engl J Med Date: 2002-05-30 Impact factor: 91.245

4. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes.

Authors: K H Lee; K W Wucherpfennig; D C Wiley
Journal: Nat Immunol Date: 2001-06 Impact factor: 25.606

5. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.

Authors: Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth
Journal: Nature Date: 2005-05-12 Impact factor: 49.962

6. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors: Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal: Lancet Date: 2008-09-22 Impact factor: 79.321

7. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Authors: Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone
Journal: Clin Immunol Date: 2009-05-14 Impact factor: 3.969

Review 8. Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age.

Authors: Suvi M Virtanen; Mikael Knip
Journal: Am J Clin Nutr Date: 2003-12 Impact factor: 7.045

9. Type 1 Diabetes TrialNet--an international collaborative clinical trials network.

Authors: Jay S Skyler; Carla J Greenbaum; John M Lachin; Ellen Leschek; Lisa Rafkin-Mervis; Peter Savage; Lisa Spain
Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691

10. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Authors: Jay M Sosenko; Jerry P Palmer; Lisa E Rafkin; Jeffrey P Krischer; David Cuthbertson; Carla J Greenbaum; George Eisenbarth; Jay S Skyler
Journal: Diabetes Care Date: 2009-12-23 Impact factor: 17.152

20 in total

Review 9. Targeting the trimolecular complex.

Authors: Aaron W Michels
Journal: Clin Immunol Date: 2013-03-05 Impact factor: 3.969

10. A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.

Authors: Bo Zhang; Rajiv B Kumar; Hongjie Dai; Brian J Feldman
Journal: Nat Med Date: 2014-07-13 Impact factor: 53.440

Immune intervention in type 1 diabetes.

Review 1. IL-1 pathways in inflammation and human diseases.

2. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.

3. Effects of insulin in relatives of patients with type 1 diabetes mellitus.

4. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes.

5. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.

6. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

7. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Review 8. Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age.

9. Type 1 Diabetes TrialNet--an international collaborative clinical trials network.

10. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

1. Regulation of mesenchymal stem cell differentiation and insulin secretion by differential expression of Pdx-1.

Review 2. Type 1 diabetes: A predictable disease.

Review 3. Treating human autoimmunity: current practice and future prospects.

Review 4. Autologous regulatory T cells for the treatment of type 1 diabetes.

Review 5. Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

6. Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Review 7. Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.

8. Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.

Review 9. Targeting the trimolecular complex.

10. A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.